New Risk • Mar 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-CA$553k). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$5.02m market cap, or US$3.66m). Ankündigung • Mar 10
Telo Genomics Corp. announced that it has received CAD 1.385 million in funding On March 9, 2026, Telo Genomics Corp. closed the transaction. The company issued Debentures for gross proceeds of CAD 545,000 in its second and final tranche. The company raised a total of CAD 1,385,000 under the offering. The Debentures bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the “Maturity Date”). The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common share of the Company (each, a “Share”) at a conversion price of CAD 0.05 per Share. The Company has no right to prepay the Debentures prior to the Maturity Date. In connection with the sale of the Debentures, the Company issued to the purchasers one transferable detachable warrant (a “Warrant”) for every CAD of principal amount of the Debentures subscribed for. The Company issued an aggregate of 10,900,000 Warrants in connection with the Second Tranche. Each Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2027. In connection with the Second Tranche, the Company paid cash finder’s fees of CAD 50 and issued 679,000 finder’s warrants (each, a “Finder’s Warrant”). Each Finder’s Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2028. The Debentures, Warrants and Finder’s Warrants issued in connection with the Second Tranche and any securities issuable upon conversion or exercise will be subject to a four month and one day hold period, expiring July 7, 2026 in accordance with applicable Canadian securities laws. The company announced that two subscribers who purchased an aggregate of CAD 00 of Debentures under the Second Tranche are considered to be related parties of the Company (the "Related Party Participation"). Specifically, John Price, the CFO of the Company, subscribed for CAD 00 of Debentures and 200,000 Warrants, and John Farlinger, a director of the Company, subscribed for CAD 35,000 of Debentures and 700,000 Warrants. Ankündigung • Jan 30
Telo Genomics Corp. Announces Chief Financial Officer Changes Telo Genomics Corp. announced that John Price has been appointed as Chief Financial Officer, effective January 30, 2026. John Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. His prior experience includes executive positions in several public companies including Assure Holdings, National Beverage, Alliance MMA, and MusclePharm. He also held various accounting and finance roles in high growth technology companies in Silicon Valley including Opera Software, GCT Semiconductor and Tessera Technologies. John Price spent the first seven years of his career with Ernst & Young. He earned a Bachelor of Science in Accounting from Pennsylvania State University. John Price succeeds Christopher Ross who has served as the Company's CFO since April 2021. Ankündigung • Jan 19
Telo Genomics Corp. announced that it expects to receive CAD 1.2 million in funding Telo Genomics Corp announced a non-brokered private placement to issue secured convertible debentures for aggregate gross proceeds of CAD 1,200,000 on January 19, 2026. The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date. The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common shares of the Company at a conversion price of CAD 0.05 per common share. For every CAD 100,000 of convertible debentures issued, Telo Genomics will issue 2 million Detachable Warrants. Each Warrant will be exercisable to acquire one common share at an exercise price of CAD 0.08 per share for a period of 12 months from the closing date. The Company has no right to prepay the Debentures prior to the Maturity Date. The Debentures, Warrants and any securities issuable upon conversion or exercise will be subject to a four month hold period in accordance with applicable Canadian securities laws. New Risk • Jan 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.2m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-CA$27k). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$4.52m market cap, or US$3.25m). New Risk • Nov 26
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$27k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.2m free cash flow). Negative equity (-CA$27k). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$5.02m market cap, or US$3.58m). Minor Risk Share price has been volatile over the past 3 months (20% average weekly change). Ankündigung • Oct 08
Telo Genomics Corp., Annual General Meeting, Dec 10, 2025 Telo Genomics Corp., Annual General Meeting, Dec 10, 2025. Location: ontario, toronto Canada Ankündigung • Jun 20
Telo Genomics Corp. Initiate Clinical Trial Forimal Residual Disease in Multiple Myeloma Telo Genomics Corp. announced that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease ("MRD") patients that are active or in remission, in a clinical trial of the Company's TeloView MM-MRD assay. Telo Genomics announced its initial MRD trial in MM on February 22, 2024, in collaboration with McGill University/Jewish General Hospital, Montreal, Canada (NCT05530096). The new collaboration with Cleveland Clinic allows Telo to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the USA, and can contribute to expediting the validation of TeloViewMM-MRD.MRD refers to the small number of remaining cancer cells post treatment. The TeloView MM-MR D test provides industry leading sensitivity for counting MRD cells, which is an established metric in assessing MRD. Critically, the TeloView MM-MRd test also offers the potential to profile the malignancy of individual cancer cells and stratify patients based on the aggressiveness of their remaining MRD. TeloView MM-MRB's proprietary approach of counting and profiling individual MRD cells has the potential to provide important, actionable information to clinicians and provide guidance in decision making, including; the extension of therapy, stopping therapy or resuming therapy, with the potential to improve clinical outcomes for MM patients post treatment. In North America, there are approximately 180,000 MM patients receiving treatment across the spectrum of different stages of the disease. Most of these patients could benefit from ongoing monitoring of treatment response using MRD assessment. Depending on the stage of the disease, patients may be monitored on a quarterly basis, leading to a total addressable market of approximately 800,000 tests per year. While the initial focus is on MM MRD, the collaboration allows for additional research that can validate assays for other utility cases in hematological malignancies, such as TeloView SMM, which is an assay that stratifies patients that are identified as having smoldering MM, a precursor to active MM. About MRD Assessment. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is. expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma. MRD treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. New Risk • May 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.4m free cash flow). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$8.50m market cap, or US$6.16m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Board Change • May 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. 3 highly experienced directors. Founder, Interim CEO, Chair of the Clinical & Scientific Advisory Board and Director Sabine Mai is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Apr 11
Telo Genomics Corp. Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025 Telo Genomics Corp. announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView®? Minimal Residual Disease (MRD) methodology, as an online publication at the ASCO Annual Meeting. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Telo's ongoing MRD clinical trials with McGill University/Jewish General Hospital have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView®?, to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine. ASCO's 2025 Annual Meeting will take place May 30 - June 3, 2025, in Chicago, Illinois. Founded in 1964, ASCO brings together more than 45,000 oncology professionals worldwide, dedicated to improving cancer care through research, education, and promotion of the highest quality patient care. ASCO is widely considered one of the most prestigious oncology research conferences of the year. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. Ankündigung • Mar 12
Telo Genomics Corp. Announces Management Changes Telo Genomics Corp. announced Mr. Guido Baechler, has assumed the role of Executive Chairman. In his expanded role, Mr. Baechler will provide more active strategic leadership, working closely with the company's founder Dr. Sabine Mai and with the executive team to further advance Telo Genomics' machine-learning (ML)-driven 3D Telomere platform in oncology, which is currently focused on multiple myeloma and prostate cancer. Mr. Baechler joined Telo Genomics' Board of Directors on February 28, 2019, as an independent director and was appointed Chairman on May 6, 2020. He brings over 30 years of leadership experience in the life sciences and medical diagnostics industries, with a strong track record of driving growth and innovation. Prior to joining Telo Genomics, Mr. Baechler spent nearly two decades at Roche Diagnostics, where he held various senior leadership roles across Europe and North America. His deep expertise in advancing cutting-edge diagnostic technologies and commercializing clinical solutions positions him well, to help guide Telo Genomics through its next phase of growth and commercialization. The Company also reports that the consulting arrangement with Sherif Louis, the former President of the Company, has not been renewed. Mr. Louis' duties will be assumed on an interim basis by members of the senior management team under the guidance of Mr. Baechler. New Risk • Feb 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$14.5m market cap, or US$9.93m). Ankündigung • Dec 24
Telo Genomics Corp. announced that it has received CAD 2.5459 million in funding On December 23, 2024. Telo Genomics Corp. has closed the transaction. it has issued 25,459,000 units at a price of CAD 0.10 per Unit for gross proceeds of CAD 2,545,900. In connection with the Offering, the Company paid a total of CAD 164,913 cash and issued a total of 1,649,130 finder's warrants as finder's fees to eligible arm's length finders. Each Finder's Warrant entitles the holder to acquire one Common Share at a price of CAD 0.10 per Common Share until December 23, 2025. A director of the Company acquired 150,000 Units in the Private Placement. The director's participation is considered to be a related party transaction as defined under Multilateral Instrument 61-101 Ankündigung • Dec 12
Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding Telo Genomics Corp. announced a non-brokered private placement of 20,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 2,000,000 on December 12, 2024. Each unit will consist of one common share of the Company and one nontransferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the closing date of the Offering, subject to acceleration. n connection with the Offering, the Company may pay finder's fees to eligible arm's length parties. The finder's fees may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. All securities to be issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance. New Risk • Dec 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.2m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$7.46m market cap, or US$5.26m). Minor Risk Shareholders have been diluted in the past year (4.6% increase in shares outstanding). New Risk • Oct 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.5m free cash flow). Earnings have declined by 27% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$9.69m market cap, or US$6.97m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Ankündigung • Oct 22
Telo Genomics Corp. Presents New Performance Data for Its Smoldering Myeloma Prognostic Test Telo Genomics Corp. announced that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International Myeloma Society (IMS) 2024 annual meeting 2024 in Brazil. The new data was based on a comparative analysis between TeloViewSMM's results and the 20-2-20 scoring model, which is currently included in the smoldering myeloma prognostic international guidelines. The TeloViewSMM prog prognostic test outperformed the 20-2-20 score in identifying both true positive (high risk patients) and true negative (low risk patients). The analysis was conducted on the same cohort of 160 SMM patients. The presented results supersede the performance of all historic attempts to stratify SMM patients to their respective risk of progression to full stage multiple myeloma and presents a viable prognostic product with high sensitivity and specificity to stratify the SMM patients. The results of this analysis were presented in an important discussion session in the IMS 2024 program by Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the National Comprehensive Cancer Network (NCCN) Myeloma Committee, and Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies. The TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, between patients that are high-risk to progress to the full stage of the myeloma disease, and those that are low-risk patients, and confirms the stability of disease in these patients. To date, this has been a critical unmet need in the management of SMM patients. High risk SMM patients may benefit from immediate treatment intervention, with a possibility to achieve cure due to recent advancement in treatment regimens. Alternatively, low risk patients can be monitored using TeloViewSMM, without exposing these patients to unnecessary and debilitating treatment. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood draw. Recent demographic studies have shown that SMM prevalence provides a significant market opportunity with an estimated 0.5% of the population over 40 years old being affected, which implies that the total TeloViewSMM addressable market could result in over 500,000 tests per year. Ankündigung • Sep 25
Telo Genomics Corp., Annual General Meeting, Nov 27, 2024 Telo Genomics Corp., Annual General Meeting, Nov 27, 2024. Location: ontario, toronto Canada Ankündigung • Sep 11
Telo Genomics Corp. Evaluates Minimal Residual Disease Biomarker Assay Technologies in Multiple Myeloma Patients as Part of the TELO-MRD Clinical Validation Study Telo Genomics Corp. announced that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Telo's MRD assays are being evaluated utilizing Adaptive Biotechnologies' clonoSEQ assay technology as a component of Telo's ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada. Telo will utilize clonoSEQ® assay technology to validate the sensitivity of its MRD assay and help to establish the clinical utility of TELO-DMRD for MRD enumeration. McGill is participating in the development of two MRD assessment prognostic tests with Telo Genomics. Telo's announced MRD evaluation study conducted with Adaptive Biotechnologies is planned to include up to ten patients that will be followed up over time. The study is open to expansion based on initial results. The first patient samples have already been analyzed. Telo's MRD clinical trials with McGill University have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine. New Risk • Jul 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (4.8% increase in shares outstanding). Market cap is less than US$100m (CA$14.2m market cap, or US$10.4m). Ankündigung • Jun 13
Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests Telo Genomics Corp. announced that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30, 2024 to June 4, 2024. The presented results described the validation and release of Telo's proprietary tool, CellSelect-Pro, that was developed using machine learning and AI platforms, to facilitate high throughput processing of samples while enhancing consistency and accuracy. The tool will favorably impact the sample processing turn-around-time (TAT) with potential cost savings of 20%-25% versus manual cell selection in the company's TeloView myeloma diagnostic tests. The innovative, proprietary algorithm was developed to identify, quantify and process myeloma plasma cells found in the patients' samples being tested. Over 5,000 myeloma positive and negative cells were used to train the AI algorithm, which was validated by processing over 20 myeloma patients' samples. CellSelect-Pro achieved accuracy of >90% and percision of >80% in the conducted validation. The tool was successfully implemented into Telo's testing workflows. The primary clinical application for CellSelect-Pro is Telo's product for smoldering multiple myeloma (SMM) patients, TeloViewSMM, offered now in the USA through the Company's SMART program (Smoldering Multiple myeloma Assessment of Risk for Transformation). CellSelect-Pro was also implemented in the workflow of Telo's active MRD (Minimal Residual Disease) clinical trial for treated multiple myeloma patients, conducted in collaboration with the McGill University, Montreal, Canada. Ankündigung • Jun 06
Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding a non-brokered private placement to issue 3,000,000 units at an issue price of CAD 0.20 per unit for the gross proceeds of CAD 600,000 on June 4, 2024. Each Unit will consist of one common share and one-half of one non-transferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share for a period of 36 months from the closing date of the Offering. In connection with the Offering, the Company may pay a finder's fee to eligible arm's length parties. The finder's fee may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. Each finder's warrant will entitle the holder to acquire one Common Share of the Company at a price of CAD 0.20 per Common Share for a period of 12 months from the closing date of the Offering. All securities to be issued pursuant to the Offering will be subject to a four-month and one day hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance. Board Change • Apr 03
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Founder, Interim CEO, Chair of the Clinical & Scientific Advisory Board and Director Sabine Mai is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. New Risk • Mar 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$8.56m market cap, or US$6.35m). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding). Ankündigung • Dec 09
Telo Genomics Corp. Announces Executive Changes Telo Genomics Corp. announced that Kris Weinberg has stepped down as the Chief Executive Officer ("CEO") of the Company. In connection with Mr. Weinberg's resignation, Telo Genomics announced that it has appointed Dr. Sabine Mai as the Company's interim CEO. Dr. Mai founded the Company, created Telo Genomics' proprietary technology, and has acted as a director of the Company since 2016. Dr. Mai is the Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, as well as a Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science at the University of Manitoba. Dr. Mai is also a director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba. New Risk • Nov 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.8m free cash flow). Earnings have declined by 6.9% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$13.5m market cap, or US$9.95m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Nov 24
New major risk - Revenue and earnings growth Earnings have declined by 6.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.8m free cash flow). Earnings have declined by 6.9% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$14.3m market cap, or US$10.4m). New Risk • Nov 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.7m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$15.7m market cap, or US$11.3m). Ankündigung • Oct 19
Telo Genomics Corp. Announces Clinical Launch of Non-Invasive Cancer Diagnostic, Teloviewsmm - an Important Commercial Milestone Achieved Telo Genomics Corp. announced the launch of its TeloViewSMM to clinicians in the United States. Combining molecular biology and artificial intelligence, the diagnostic platform performs 6-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes. TeloView has the potential to characterize multiple cancers, identify their current level of genomic instability and therefore predict their progression. The Company's initial clinical launch will focus on testing for "Smoldering Multiple Myeloma (SMM)" the precursor for Multiple Myeloma, a blood-based bone marrow cancer. Approximately 50% of patients with SMM will develop full Multiple Myeloma. The test is available for physicians to order under the SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation) protocol, an observational study intended for oncology/hematology physicians and their staff in the U.S., to gain experience ordering and utilizing the TeloViewSMM assay. SMART follows a positive industry trend toward introducing novel molecular testing tools in an observational construct to efficiently gather information and feedback from clinicians and their teams. While the initial launch of TeloViewSMM will be conducted as a single-site CLIA (Clinical Laboratory Improvement Amendments) model, commercial-scale delivery of testing will be accomplished in partnership with large reference labs where FISH and microscopy resources are available and scalable. The company is also developing products and use cases for the biopharma and CRO segment and has an active business development pipeline focused on CDx opportunities and contract research. Ankündigung • Oct 13
Telo Genomics Presents Positive Results in Assessing Minimal Residual Disease in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting Telo Genomics Corp. announced that it has participated in the International Myeloma Society (‘IMS’) annual meeting that took place in Athens, Greece during the last week of September 2023. The company presented positive results in assessing minimal residual disease (‘MRD’) in multiple myeloma (‘MM’). The data presented demonstrated repeatable sensitivity three-fold higher than what is currently being used in clinical practice. The presented results will be published in the journal of Clinical Lymphoma, Myeloma & Leukemia. Telo's MRD test pioneers an innovative, proprietary and minimally invasive technology with the potential to facilitate MRD assessment in most MM patients. The test is designed to monitor MM patients' performance post-treatment to predict patients' relapse or to guide an informed decision to terminate maintenance therapy for patients who remain in remission, a critical unmet need in the clinic. The data presented at the IMS meeting represents the initial phase of an ongoing prospective clinical trial to monitor disease progression in post-treatment patients, by measuring and profiling MRD in these patients using Telo's proprietary technology. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. Ankündigung • Sep 26
Telo Genomics Corp., Annual General Meeting, Nov 30, 2023 Telo Genomics Corp., Annual General Meeting, Nov 30, 2023. New Risk • Jun 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$21.3m market cap, or US$16.2m). Ankündigung • Jun 16
Telo Genomics Corp. announced that it has received CAD 2.833875 million in funding June 14, 2023, Telo Genomics Corp. closed the transaction. The company issued 11,335,500 units at an issue price of CAD 0.25 per unit for the gross proceeds of CAD 2,833,875. The warrants will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share until June 13, 2025. The company paid a total of CAD 173,503.75 finder's fees in cash and issued a total of 694,015 finder's warrants. Each Finder's Warrant entitles the holder to acquire one common share of the Company at a price of CAD 0.25 per share until June 13, 2024. The securities issued pursuant to the Offering are subject to a statutory four month hold period ending on October 14, 2023 in accordance with applicable securities laws. Ankündigung • Jun 13
Telo Genomics Corp. Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023 Telo Genomics Corp. presented the results of its latest study on June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunction with the Mayo Clinic, was conducted to confirm the utility of the TeloView technology to identify newly diagnosed multiple myeloma (NDMM) patients with a high-risk to relapse within 1 year while receiving first-line therapy. In this 174-patient study, the TeloView MM assay was used to predict the outcome of patients in 2 cohorts. Cohort 1 exclusively included patients who relapsed within 1 year of initiating first line therapy. Cohort 2 was made up of patients that responded to therapy and had stable disease for over 3 years after starting therapy. The TeloView MM assay proved to be a powerful predictive tool in both groups, achieving combined accuracy of over 80%. Predicting NDMM patient response to first line therapy is a critical unmet clinical need. In current clinical practice, patients will remain on a specific treatment regimen until relapse and then be switched to an alternative regimen. The cost of therapy can range between $100,000 - 150,000 per year and most NDMM patients do relapse on first line therapy within 24 months. TeloView-MM testing for the newly diagnosed population has the potential to allow treating physicians to make informed decisions to switch high-risk patients to an alternative treatment proactively and avoid the relapse event. The TeloView-MM assay has the potential to benefit over 35,000 NDMM patients annually in the US with a total addressable market of approximately 300,000 tests per year. Ankündigung • May 20
Telo Genomics Corp. announced that it expects to receive CAD 2 million in funding Telo Genomics Corp. announced a non-brokered private placement of 8,000,000 units at an issue price of CAD 0.25 per unit for the gross proceeds of CAD 2,000,000 on May 19, 2023. Each Unit will consist of one common share of the Company and one-half of one non-transferable common share purchase warrant. Each Warrant will entitle the holder to acquire one additional Common Share at a price of CAD 0.40 per Common Share for a period of 24 months from the date of issuance. In connection with the Offering, the Company may pay a finder's fee to eligible arm's length parties. The finder's fee may consist of a cash fee equal to 7% of the gross proceeds raised under the Offering and finder's warrants equal in number to 7% of the Units sold under the Offering. Each finder's warrant will entitle the holder to acquire one Common Share of the Company at a price of CAD 0.25 per Common Share for a period of 12 months from the date of issuance. The securities issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance. Ankündigung • May 06
Telo Genomics' Multiple Myeloma Drug Resistance Study Results Selected for Presentation At the 2023 European Hematology Congress Telo Genomics Corp. announce that the abstract submitted to the European Hematology Association (EHA) 2023 annual congress was accepted for presentation and will be published in the official proceedings of the meeting. The abstract summarizes the results to date of the second clinical study that Telo is conducting in collaboration with the Mayo Clinic. The study's objective is to validate the utility of TeloView technology in identifying newly diagnosed multiple myeloma (NDMM) patients, who might develop resistance to first line therapy within 12 months from the point of diagnosis. The study also aims to confirm multiple myeloma (MM) disease stability for patients who go into remission. This important subgroup may have a low probability to relapse for up to 3 years, over which time they can monitored with TeloView. The results summarized in the abstract are under embargo until the abstract is published online on the EHA website on May 11, 2023. Acceptance of the NDMM study data for presentation and publication at EHA 2023 highlights Telo's successful path in establishing TeloView technology as an important predictive/prognostic tool in the management of MM across several stages of the disease. Telo has recently announced that the results of its smoldering multiple myeloma (SMM) clinical study, also conducted in collaboration with the Mayo Clinic, were accepted for presentation and publication at the American Society for Clinical Oncology (ASCO) 2023 annual meeting, to be held from June 2-6th, 2023. Telo's lead product is designed to identify high-risk SMM patients who may receive earlier treatment intervention before the patient develops symptoms from active MM. Notably, the test will also benefit the larger subset of low-risk SMM patients, who have a more stable form of the disease, and do not require immediate treatment. These patients can be regularly monitored using Telo's test, importantly, stable SMM patients may be tested up to every three months. The Company's second assay is designed to identify NDMM patients who are most likely to develop treatment resistance and relapse earlier than expected. Identifying these patients will enable physicians to modify treatment regimens in real time. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important unmet clinical need in the treatment of MM. The total addressable market for both of Telo's MM assays is over 750,000 tests per year in the US. Ankündigung • Nov 11
Telo Genomics Corp. Launches A Minimal Residual Disease Clinical Trial in Multiple Myeloma Telo Genomics Corp. announce that it is launching a clinical trial to monitor multiple myeloma disease progression in post-treated patients, by measuring and profiling the minimal residual disease in these patients. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The study will be conducted prospectively on diagnosed MM patients eligible for bone marrow transplantation, it has two objectives that will potentially enable TELO to develop two prognostic tests for monitoring myeloma MRD. MRD refers to myeloma plasma cells that remained in the patient's system post treatment. The two objectives include: i) quantify the number of MRD cells circulating in the patient's blood post treatment, and ii) profile the circulating MRD cells using TeloView technology to assess disease aggressiveness in individual MRD cells. The two MRD tests for MM are designed to be liquid biopsy-based, which is at the forefront of precision medicine. Monitoring MRD in oncology is evolving to be an important prognostic tool for assessing the depth of a patient's response to treatment; it can also help in identifying patients at higher risk of relapse and potentially guide response-based treatment paradigms in several hematological disorders including MM. In North America there are approximately 180,000 MM patients receiving treatment at any time across the different stages of the disease. Most of these patients may benefit from ongoing monitoring of treatment response using MRD assessment. To date, the prognostic power of MRD assessment is not fully realized in the clinic for MM patients, this is due to the limited capability of the current technologies, which can only inform on MRD cell count (enumeration). Enumeration alone was proven over the years to be inadequate in providing accurate representation of the risk of disease progression. Furthermore, each of the current MRD assessment technologies has its own technical limitation rendering it inapplicable to several MM patient populations. TeloView technology employs a patented liquid biopsy enumeration methodology that will facilitate the quantification of MRD in the vast majority of MM patients. In addition, TELO can assess the genomic instability of the MRD cells using TeloView technology, which has the potential to provide accurate assessment of disease aggressiveness beyond merely the cell count and has the potential to more accurately inform on the risk of disease progression. Telo Genomics anticipates receiving the first patient samples during First Quarter of 2023. The clinical validation of the first MRD test in development, focused on MRD enumeration, is expected to be completed within 12-18 months, followed by the validation of the second test using TeloView to profile the genetic instability of the MRD cells. Ankündigung • Oct 20
Telo Genomics Corp. Appoints Richard A. Bender to Establish and Chair its MM Clinical Advisory Board Telo Genomics Corp. announced that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma (MM) clinician, key opinion leader and medical diagnostics expert to establish and chair company's MM clinical advisory board (Advisory Board). Dr. Bender is a board-certified oncologist who brings more than 40 years of experience in hematologicalmalignancy with a special focus on MM. He received his medical degree from the UCLA School of Medicine and completed his internship and residency at UCLA-Harbor General Hospital followed by a hematology/oncology fellowship at the National Cancer Institute. His past titles include Medical Director for Hematology/Oncology for Quest Diagnostics, Medical Director for Hematology/Oncology for Kaiser Permanente in San Diego, and Chief Medical Officer for both Agendia and Signal Genetics. Dr. Bender has also served on the executive board of the San Diego Hospice and American Cancer Society and has been retained by the FDA as a member of the Hematology and Pathology Devices Advisory Committee. He continues to teach at the UCLA School of Medicine and has authored more than 80 peer-reviewed scientific articles and book chapters. Ankündigung • Sep 30
Telo Genomics Corp., Annual General Meeting, Dec 01, 2022 Telo Genomics Corp., Annual General Meeting, Dec 01, 2022. Ankündigung • Sep 15
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study Telo Genomics Corp. announced that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma ("SMM"), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints. In July 2022, the Company announced that it had completed processing of the patient samples related to the SMM study and submitted the laboratory results to the Mayo Clinic for review and analysis. TELO intends to submit the final findings of the study for presentation at the American Society of Hematology (ASH) annual meeting scheduled for December 2022. The Company's TeloView®-based test for SMM has the potential to identify high-risk SMM patients who will benefit from earlier treatment intervention; significantly, the test also has the potential to predict the larger subset of low-risk patients who have a more stable form of the disease and do not require treatment. Low-risk SMM patients may be tested up to every three months on an ongoing basis to monitor their status without the need for treatment intervention. TELO, in consultation with industry leaders, estimates that there are over 200,000 patients in the USA that may benefit from its TeloView® test for SMM, with a potential total addressable market of over 500,000 tests per year. Based on the Company's interim results and as part of its commercialization plan to introduce TeloView® as a prognostic test across the spectrum of multiple myeloma ("MM") disease; TELO is also pleased to announce that it will be forming a MM clinical advisory board. The board will be made up of leading clinicians in the field with the purpose of guiding the Company's product launch and clinical adoption efforts for the TeloView® test for MM and its precursors. Ankündigung • Aug 18
Telo Genomics Completes Processing of Multiple Myeloma Drug Resistance Patient Samples Telo Genomics Corp. announces the completion of the laboratory processing and analysis of patient samples related to its multiple myeloma drug resistance clinical study. The patient samples were provided by the Mayo Clinic as part of an ongoing collaboration to evaluate the Company's prognostic technology for multiple myeloma ("MM"). TELO's study results have now been submitted back to the Mayo Clinic for review and analysis. This is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology to address multiple unmet clinical needs across the spectrum of MM.TELO's ongoing collaboration with the Mayo Clinic includes clinical studies in the development of prognostic tools to address two specific unmet clinical needs in the management of MM including: assess the risk of precursor smouldering myeloma (SMM) patients who may benefit from either immediate intervention for high-risk SMM or active continual monitoring for stable SMM; and identify MM patients who will develop resistance to first-line treatment within two years, and may benefit from an alternative treatment regimen. In July 2022, TELO announced the completion of processing the patient samples related to its lead product for SMM patients. The Company announces herein the completion of processing the samples for the second clinical study for MM patients who will develop resistance to first-line treatment.MM is a challenging and potentially deadly blood cancer that affects plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with 35,000 new cases every year in the US, with approximately 180,000 patients receiving treatment at any given time. MM treatment usually includes various combinations of drugs, each having different mechanisms of action at a cost of up to USD 150,000 per year per patient for the standard of care. However, most patients will develop resistance to treatment and relapse within a median of 2 years. Identifying these patients who will develop drug resistance, relapse early and would benefit from altering their treatment, remains an unmet need in the management of MM. Once relapsed, MM patients are commonly transitioned to a different treatment regimen, where they will continue to benefit from active monitoring to identify the risk of further relapses. The identification of patients at high-risk of relapse presents the opportunity for closer patient monitoring and consequently, dynamic real-time tailoring of treatment, likely leading to improved survival, longer-remission in patient outcomes, and potentially decreased requirement of more costly interventions like the newly approved CAR-T cell treatment that exceeds $400,000 per treatment. In the US, the incidence rate and number of patients currently receiving treatment provides an estimated addressable market of over 500,000 tests per year for ongoing patient monitoring at 3 month intervals. Ankündigung • Jul 14
Telo Genomics Launches Clinical Study of Drug Resistance Test for Multiple Myeloma Telo Genomics Corp. announced that it has commenced the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma ("MM") patients that are at high-risk of developing treatment resistance. This study is the second study being carried out in collaboration with the Mayo Clinic to evaluate the Company's prognostic technology to address multiple unmet clinical needs in MM. MM is a highly challenging and deadly blood cancer that forms in plasma cells, a type of white blood cell. Symptoms include bone pain, frequent infections, fatigue, and weight loss. There are currently several combinations of drugs in clinical use for the treatment of MM and most patients initially respond to treatment and enter remission. However, disease remission is typically followed by treatment resistance and relapse, this can occur from as early as 3 months from initiation of treatment until 24 months. Identifying patients who will develop drug resistance prior to relapse is a critical unmet need in the management of MM. Addressing this unmet need will allow healthcare providers to identify patients at high-risk of drug resistance and modify their treatment regimens accordingly. The identification of patients at high-risk of treatment resistance presents the potential for regular and continuous patient monitoring and consequently, dynamic real-time treatment modification. The incidence rate of MM in the USA is approximately 35,000 cases per year with an estimated potential total addressable market of over 250,000 tests per year. In 2020, TELO entered into a collaboration agreement with the Mayo Clinic to conduct clinical studies targeting the development of two clinical prognostic tests for MM. On July 6, 2022, TELO announced the completion of the processing of clinical samples related to its lead product in development for smouldering multiple myeloma (SMM) and is in the process of data review and analysis. For further clarification, the clinical study being launched for drug resistance, the subject of this press release, is the second prognostic test in development in collaboration with the Mayo Clinic. Ankündigung • Jun 02
Telo Genomics Corp. Completes the Validation of Suite of Proprietary Automation Tools Telo Genomics Corp. announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow. The validation was conducted on a subset of smoldering multiple myeloma (SMM) patient samples that were received in collaboration with the Francois Baclesse Cancer Center, Caen, France. TELO recently completed a series of projects with the goal to automate and enhance accuracy andefficiency of its novel diagnostic platform. These projects included: i) increased automation and batch processing of the microscopy aspects of the assay, ii) developed machine learning and artificial intelligence algorithms to facilitate automated target cell selection, a key step in the single cell analysis that enriches the value of TeloView analytics, and iii) enhanced the processing capacity of the TeloView platform. The implementation of these automation tools is expected to increase the efficiency and productivity of the TeloView workflow by over 40%. The key advantages of these improvements include: i) reduced sample processing time, ii) simplified, and less operator-dependent processes leading to greater precision, iii) lowered labor costs, and iv) a net reduction of sample processing steps. In short, the developed bundle of automation tools will decrease assay turnaround time, a key value enhancing factor that will drive the adoption of the technology in the clinic. Ankündigung • Mar 10
Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test Telo Genomics Corp. announced that it has received clinical samples from its collaborator, Mayo Clinic, to conduct the clinical validation of the Company's lead product in development, its TeloView® prognostic test for segregating high risk and low risk smoldering multiple myeloma (SMM) patients. TELO announced on March 28, 2021, that it had completed the feasibility stage of its ongoing clinical studies in collaboration with Mayo Clinic. The completion of the feasibility stage has allowed the Company to advance to the clinical validation stage, an important step in the process to make its TeloView® test for SMM commercially available for clinical use. SMM is a biologic precursor to multiple myeloma, a deadly cancer that forms in plasma cells, a type of white blood cell. Typically, SMM is asymptomatic, but approximately 15% of SMM patients transition to active multiple myeloma, which involves marked pain, the risk of bone fractures, and other debilitating symptoms. Identifying high risk SMM patients, who will ultimately transition to active multiple myeloma is a critical unmet need in the management of multiple myeloma. The incidence rate of multiple myeloma is approximately 35,000 in the USA. The Company's TeloView® test for SMM has the potential to identify high risk SMM patients who will benefit from earlier treatment intervention, and of equal importance, the test has the potential to predict the subset of low risk patients who have a more stable form of the disease and do not require treatment. Low risk SMM patients may be repeatedly tested up to every three months to monitor their status without the need for intervention. TELO, in consultation with industry leaders, estimates that there are over 200,000 patients in the USA that may benefit from its TeloView® test for SMM, with a potential total addressable market of over 500,000 tests per year. The development of the Company's TeloView® test for SMM has the potential to resolve a critical unmet need in the management of multiple myeloma. Currently a number of clinical trials are focused on treating high risk SMM patients, however, the progress of these trials is constrained by the lack of an effective tool to identify and segregate high risk SMM patients and low risk SMM patients. Furthermore, the treatment cost of a full stage active multiple myeloma patient can exceed $100,000 per year. Treating the 80% of the SMM patients who are in the stable, low-risk category, would create an unnecessary cost to the healthcare system. Ankündigung • Feb 04
Telo Genomics Corp. Appoints Ron McGlennen as Board of Director Telo Genomics Corp. announced that Dr. Ron McGlennen, President and Founder of the medical laboratory Access Genetics, Minnesota, USA, has joined its Board of Directors. Dr. McGlennen brings unique and valuable expertise to TELO's board with extensive experience in successfully introducing novel diagnostics technologies into clinical laboratories across the USA. Dr. McGlennen brings over 30 years of leadership in the development and commercialization of innovative diagnostic and prognostic technologies across multiple disease areas. Over the past decades, Dr. McGlennen has acted as medical director of several clinical laboratories across the USA. He is currently Associate Professor of Pathology at the University of Minnesota Medical School and has published more than 70 peer reviewed publications and book chapters. Ankündigung • Jan 20
Telo Genomics Corp. Advances Its Lead Product and Implements Automation to Its Workflow Telo Genomics Corp. announced the launch of a validation study to accelerate the commercialization of its lead product in development for smoldering multiple myeloma (SMM) patients. The company also announced that it has recently implemented in its workflow several proprietary automation solutions that employed cutting edge machine learning and artificial intelligence algorithms. The company has recently received the SMM patient samples pertaining to a validation study that the company is launching. The clinical study will be conducted under the clinical leadership of Dr. Hans Knecht, Head of Hematology, Jewish General Hospital & McGill University, Montreal, Canada and TELO's Clinical Advisor. The samples were received in collaboration with the Francois Baclesse Cancer Center, Caen, France. The launched study goal is to accelerate the validation of the company's ongoing collaboration with the Mayo clinic to develop the company's lead product, a prognostic test for smoldering multiple myeloma (SMM) patients. The company's lead test in development for SMM patients has the potential to identify high risk SMM patients that will benefit from immediate treatment intervention, and equally important, the test also has the potential to confirm disease stability of low risk SMM patients who can be safely monitored and tested as often as every three months. The total addressable market for this TeloView test will is conservatively estimated to be over 200,000 SMM patients in the USA alone with the potential for over 500,000 tests per year. Multiple Myeloma (MM) is a cancer that forms in plasma cells, a type of white blood cells. To date MM is a deadly incurable cancer. MM is preceded by 2 asymptomatic forms of the disease (precursors), recognized as monoclonal gammopathy of undetermined significance (MGUS) and SMM. MGUS progression rate to full stage MM is approximately 1% per year, hence considered low risk of progression. SMM progression rate to full stage MM is 15% per year. The progression of SMM patients to full stage MM constitutes a major concern to health care professionals in the management of the MM disease. The company's lead product in development for SMM is expected to provide healthcare professionals a long-waited-for solution for the management of this group of patients. Currently SMM patients are monitored but not treated. The MM clinical community is diligently seeking non-invasive prognostic modalities to identify high risk SMM patients and confirm the disease stability of low risk SMM patients. The urgency in establishing a prognostic tool for SMM patients was repeatedly emphasized by MM key opinion leaders during the American Society of Hematology (ASH) annual meeting that took place in December 2021, and the International Myeloma Workshop that was held in September 2021. Currently a number of clinical trials to treat SMM patients are ongoing, however the progress of these trials is restrained by the lack of an effective tool to identify high risk patients, a true unmet market need. The treatment cost of diagnosed full stage MM patient exceeds $100,000 per year. Treating any of the 80% of stable SMM patient group unnecessarily at this cost would create a substantial burden on health care systems. The company also announced that over the last 12-months it has conducted several internal R&D projects to enhance its throughput, maximize accuracy and elevate its efficiency. These projects included: i) increased automation and batch processing to the microscopy component of the workflow, ii) introduction of machine learning algorithms to facilitate automated target cell selection, a key step in the single cell analysis that enriches the value of TeloView analytics, and iii) enhanced the processing capacity of the TeloView platform. These projects are now completed, validated and implemented. The implementation of these enhancements to the company's workflow increased the efficiency and productivity of TeloView by over 40%. The key advantages of these improvements include: i) expedite the completion of clinical studies, ii) simplify the process of technology adoption by potential partners or licensees in the future, iii) lower sample processing cost by allowing the company's high qualified human assets to maximize multitasking, iv) minimize the probabilities of human introduced errors. Recent Insider Transactions Derivative • Nov 07
Independent Director exercised options to buy CA$102k worth of stock. On the 29th of October, Hugh A. Rogers exercised options to buy 275k shares at a strike price of around CA$0.20, costing a total of CA$55k. This transaction amounted to 35% of their direct individual holding at the time of the trade. Since March 2021, Hugh A.'s direct individual holding has increased from 787.96k shares to 1.06m. This was the only transaction from an insider over the last 12 months. Ankündigung • Jul 07
Telo Genomics Corp. announced that it has received CAD 2.28775 million in funding On July 5, 2021, Telo Genomics Corp. (TSXV:TELO) closed the transaction. The company has issued 390,000 units for the gross proceeds of CAD 195,000 in its second and final tranche. The company has raised CAD 2,287,750 in the transaction. A director of the Company participated in the Offering by subscribing for 10,000 Units. Each Warrant issued in the transaction will entitle the holder to acquire one additional Common Share at a price of CAD 0.75 per Common Share until January 2, 2023. The company has paid CAD 10,150 to PI Financial Corp. and CAD 3,500 to Canaccord Genuity Corp. The Company also issued finder's warrants to eligible finders as follows: 20,300 Finder's Warrants to PI Financial Corp. and 7,000 Finder's Warrants to Canaccord Genuity Corp. Each Finder's Warrant entitles the holder to acquire one common share of the Company at a price of CAD 0.50 per share until July 2, 2022. The securities issued pursuant to this tranche of the Offering are subject to a statutory four month hold period ending on November 3, 2021 in accordance with applicable securities laws. The Offering is subject to final approval from the TSX Venture Exchange. Ankündigung • Jun 19
Telo Genomics Corp. announced that it expects to receive CAD 1.5 million in funding Telo Genomics Corp. (TSXV:TELO) announced a non-brokered private placement of 3,000,000 units at issue price of CAD 0.50 per unit for gross proceeds of CAD 1,500,000 on June 18, 2021. Each unit consists of one common share and one-half of one non-transferable common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at an exercisable price of CAD 0.75 per common share for a period of 18 months from the closing of the transaction. The company may pay finders fees of 7% of the gross proceeds and finders warrants equal to 7% of units sold in the transaction. Each finder’s warrant will entitle the holder to acquire one common share of the company at a price of CAD 0.50 per common share for a period of 12 months from the date of issuance. The securities to be issues are subject to a hold period of four month from the date of issuance. The transaction is subject to approval from TSX Venture Exchange. Is New 90 Day High Low • Feb 09
New 90-day high: CA$0.94 The company is up 327% from its price of CA$0.22 on 10 November 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 29% over the same period. Ankündigung • Feb 04
Telo Genomics Appoints Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy Telo Genomics Corp. announced that the Company has entered into a consulting agreement with the biomedical industry veteran Gregg Mayer, Founder & Principal of BioCore Strategies, LLC, Boston, Massachusetts, USA, and former executive of Abbott Diagnostics, Siemens and a number of early-stage biopharma and medical device companies, both public and privately held. Mr. Mayer will lead TELO’s efforts to develop and execute the Company’s industry partnership strategy with Biopharma and Diagnostics industries. Is New 90 Day High Low • Jan 20
New 90-day high: CA$0.54 The company is up 192% from its price of CA$0.18 on 21 October 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period. Ankündigung • Jan 09
Telo Genomics Corp., Annual General Meeting, Mar 04, 2021 Telo Genomics Corp., Annual General Meeting, Mar 04, 2021. Is New 90 Day High Low • Dec 30
New 90-day high: CA$0.27 The company is up 20% from its price of CA$0.22 on 30 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period. Ankündigung • Nov 18
Telo Genomics Corp. Announces the Positive Results of Its Smoldering Multiple Myeloma Proof of Concept Study Telo Genomics Corp. announced the positive results of its smoldering multiple myeloma proof of concept study, recently published within the proceedings of the American Society of Hematology annual meeting 2020. In this published study, TeloView®'s quantitative and spatial analysis of 6 key parameters of telomeres was conducted on a total of 26 patients that were diagnosed with smoldering multiple myeloma. The cohort included 21 stable patients who remained at the smoldering stage for over 5 years and 5 high- risk patients that progressed to the active multiple myeloma stage within 2 years from point of diagnosis. A high level of statistical significance was observed across all of the 6 parameters measured by TeloView®, and the analysis distinguished between the group of patients that remained stable with smoldering multiple myeloma from the group that progressed to active multiple myeloma in 26 out of the 26 patients-cohort. The study was conducted blindly on the diagnostic specimens suggesting the capability of TeloView® analysis to stratify smoldering multiple myeloma patients at the point of diagnosis. These results have the potential to guide evidence-based decisions to treat smoldering multiple myeloma patients with a high risk of progression, addressing a critical unmet clinical need in the management of multiple myeloma. Telo Genomics is conducting further studies on expanded cohorts of patients to further validate the results obtained from this proof of concept study, and to confirm the utility of its TeloView® technology to predict the progression of smoldering multiple myeloma in patients. Ankündigung • Nov 12
Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’S Disease TeloGenomics Corp. announced that it has received final approval and grant of three of its pending patent applications including: Diagnostic Methods for Hematological Disorders (Hematological Cancers) - Canada. Methods for Characterizing and isolating circulating tumor cell subpopulations (Liquid biopsy) - Canada. Methods of Diagnosing Alzheimer’s Disease - Europe. TELO has already been granted final patents governing its intellectual property (“IP”) for hematological cancers in the USA, and Alzheimer’s Disease in the USA and Canada. TELO’s patent application on liquid biopsy in the USA is still pending. TELO has secured intellectual property protection in various jurisdictions around the world and owns a portfolio of patents and pending patent applications in the United States, Canada and the EU. The scope of the IP covers its core technology and specific applications of the technology. In addition to the patents and pending patent applications, TeloView® is protected as a trademark in the USA, Canada, Europe and Israel. Ankündigung • Oct 14
Telo Genomics Corp. Announces That Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within Ash 2020 Proceedings TeloGenomics Corp. announced that its abstract submitted to the American Society of Hematology (ASH) annual meeting 2020, reporting on positive results achieved from a diagnostic/prognostic smoldering multiple myeloma (SMM) ‘proof of concept’ study, was selected for online publication. The abstract will be included in the November supplemental issue of the scientific journal Blood, published by ASH. The SMM proof of concept study was conducted in collaboration between TELO Genomics and Dr. Sabine Mai’s research laboratory. The study was conducted using TELO’s proprietary TeloView® technology. Dr. Mai is co-Founder, Director and Chair of the Clinical and Scientific Advisory Board of TELO. The specific data from the study has been embargoed until the publication of the journal. The American Society of Hematology is a professional organization representing healthcare professionals involved in the management of blood disorders including blood cancers. The ASH annual meeting is considered one of the top clinical international meetings focused on blood cancers and hematological malignancies. ASH annual meeting attracts more than 30,000 attendees every year, predominantly clinicians from all over the world. Smoldering multiple myeloma is a an asymptomatic precursor to active multiple myeloma (MM), a highly challenging blood cancer that forms in plasma cells, a type of white blood cell. There is an increasing industry trend towards trying to identify high-risk SMM patients to initiate early treatment and achieve better clinical outcomes (Kapoor & Rajkumar 2019). The MM annual incidence rate is approximately 32,000 newly diagnosed cases in the USA per year, with approximately 250,000 cases of SMM, and 10-15% of SMM patients progress to active MM every year. Is New 90 Day High Low • Oct 14
New 90-day low: CA$0.20 The company is down 24% from its price of CA$0.27 on 16 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.